COVID-19
COVID-19 treatments: under evaluation
The European Medicines Agency (EMA) is evaluating potential COVID-19 treatments to enable promising medicines to reach patients in the European Union (EU) as soon as possible.
EMA’s CHMP is evaluating the following COVID-19 treatments:
| Treatment | Treatment developer | Start of rolling review | More information |
|---|---|---|---|
| REGN-COV2 (casirivimab / imdevimab) | Regeneron Pharmaceuticals, Inc. and F. Hoffman-La Roche, Ltd (Roche) | 01/02/2021 | |
| Regdanvimab | Celltrion | 24/02/2021 | |
| Bamlanivimab and etesevimab | Eli Lilly | 11/03/2021 | |
| Sotrovimab | GlaxoSmithKline and Vir Biotechnology, Inc. | 07/05/2021 | EMA starts rolling review of sotrovimab (VIR-7831) for COVID-19 |
EMA’s CHMP is evaluating the marketing authorisation application of the following COVID-19 treatment:
| Treatment | Treatment developer | Start of marketing authorisation evaluation | More information |
|---|---|---|---|
| Olumiant (baricitinib) | Eli Lilly Nederland B.V. | 29/04/2021 | EMA starts evaluating use of Olumiant in hospitalised COVID-19 patients requiring supplemental oxygen |
Kineret (anakinra) | Swedish Orphan Biovitrum AB (publ) | 19/07/2021 |